In 2009 Argolyn Biosciences filed for Chapter 7 Bankrupcy and some time thereafter closed its doors. Preclinical studies of its pain drug showed that in the highly competitive tconditions that define the pain market at the time. the firm's line-up just wasn't potent enough, Headquartered in Durham, NC, the firm had maintained research facilities in South Carolina, A privately held biopharmaceutical company, Argolyn had been organized around developing novel peptide drug candidates to treat psychosis, pain, and other serious diseases and disorders. The firm's most advanced development candidate had been ABS201, a first-in-class peptide derivative at the time in preclinical development for the treatment of schizophrenia. Other product candidates in the firm's portfolio, were developed using proprietary amino acid analog substitution technology which enables the rapid and efficient discovery of novel, peptide-based drug candidates.
